According to Zhitong Finance App, Zhaoke Ophthalmology-B (06622.HK) announced that on July 13, 2026, the company's innovative drug YUVEZZI™ (2.75% cabacholine and 0.1% bromonidine tartrate eye drops) has been approved by the Macao Special Administrative Region Government Drug Administration for the treatment of presbyopia.

Zhitongcaijing · 3d ago
According to Zhitong Finance App, Zhaoke Ophthalmology-B (06622.HK) announced that on July 13, 2026, the company's innovative drug YUVEZZI™ (2.75% cabacholine and 0.1% bromonidine tartrate eye drops) has been approved by the Macao Special Administrative Region Government Drug Administration for the treatment of presbyopia.